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Myocardial Infarct Size Reduction With Pexelizumab
The Role of Chance Is Patently Clear*
C. Michael Gibson, MS, MD, Yuri B. Pride, MD
Boston, MassachusettsThe goal of ST-segment elevation myocardial in-
farction (STEMI) management is rapid and sus-
tained reperfusion of the infarct-related artery
(1–3). Primary percutaneous coronary intervention
(PCI) is the preferred reperfusion method if it can
be performed promptly and by an experienced
operator (4). Despite widespread improvements in
clinical pathways to improve door-to-balloon time
and the development of novel antiplatelet and
antithrombotic agents and subsequent improved
clinical outcomes, STEMI remains a cause of con-
siderable morbidity and mortality (5). As such,
numerous pharmacologic and device-based strate-
gies have been developed with the aim of improving
outcomes among STEMI patients.
See page 52
Although primary PCI sufficiently restores epi-
cardial patency in the majority of STEMI patients,
a large subset suffer from impaired myocardial
perfusion, which has been associated with larger
infarct size and a higher incidence of adverse
cardiovascular events (6). Impaired myocardial per-
fusion may result from embolization of thrombotic
and atherosclerotic debris and platelet microag-
gregates, endothelial dysfunction, inflammatory
changes, or a combination of these events that occur
in the myocardial microcirculation downstream of
ruptured plaque.
The role of inflammation, specifically the com-
plement pathway, in myocardial injury following
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Cardiovascular Division, Department of Medicine, Beth
Israel Deaconess Medical Center, Harvard Medical School, Boston,
Massachusetts.STEMI has been an area of active investigation (7).
The C5 component of the complement pathway,
when cleaved via activation of more proximal com-
ponents of the pathway, yields C5a, a proinflam-
matory cytokine, and C5b, which initiates produc-
tion of the membrane attack complex, a multimeric
protein that inserts itself into the cell membrane
and leads to membrane destabilization and, ulti-
mately, cell death. Therefore, inhibition of the
cleavage of C5 into C5a and C5b would appear to
be an attractive target in the reduction of infarct size
and, potentially, adverse clinical events following
STEMI.
Pexelizumab, a humanized monoclonal antibody
that binds C5, showed promise in a phase 2 study of
STEMI patients undergoing primary PCI, the
COMMA (COMplement inhibition in Myocardial
infarction treated with Angioplasty) trial (8). Para-
doxically, administration of intravenous pexeli-
zumab following primary PCI did not lead to a
significant reduction in enzymatic infarct size, but
was associated with a significant reduction in mor-
tality (5.9% vs. 1.9%, p  0.014). The authors
postulated that although pexelizumab had no effect
on infarct size, as might have been expected, its
anti-inflammatory properties must have had some
unmeasured pleiotropic effect(s) in order to lead to
a reduction in mortality. Unfortunately, a subse-
quent phase 3 trial of high-risk STEMI patients,
the APEX-AMI (Assessment of Pexelizumab in
Acute Myocardial Infarction) study, did not con-
firm this reduction in either mortality or in the
composite of death, shock, and congestive heart
failure at 30 or 90 days following STEMI (9).
In this issue of iJACC, Patel et al. (10) present the
cardiac magnetic resonance (CMR) substudy of the
APEX-AMI trial. In this 99-patient substudy, the ad-
ministration of pexelizumab was associated with a signif-
icant reduction in infarct size and a higher left ventricular
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62jection fraction compared with placebo, a surpris-
ng result, considering administration of pexeli-
umab had no significant effect on mortality, shock,
r congestive heart failure in the entire study
opulation.
At first blush, the results of this substudy appear
o present the opposite paradox from what was seen
n the COMMA trial: in COMMA, pexelizumab
id not reduce enzymatic infarct size but was
ssociated with a significant reduction in mortality;
n APEX-AMI, pexelizumab was associated with a
eduction in CMR infarct size but had no effect on
ortality.
The authors present 3 possible explanations for
he significantly smaller infarct size in the pexeli-
umab group: 1) that pexelizumab does, in fact,
educe infarct size, but has some unknown delete-
ious effect; 2) that CMR may have been inaccurate;
r 3) that there was selective bias inherent in this
ubgroup analysis.
Upon closer inspection of the patients enrolled in
he CMR substudy of APEX-AMI, however, it
ecomes readily apparent why patients who re-
eived pexelizumab had, on average, smaller infarct
ize: they were significantly and substantially more
ikely to have a patent culprit artery at the time of
nitial angiography (42.9% with Thrombolysis In
yocardial Infarction [TIMI] flow grade 2 or 3 in
he pexelizumab group versus 14.6% in the placebo
roup). Although pexelizumab was administered
rior to balloon inflation, it is unlikely that it had
uch a dramatic effect on culprit artery patency and
ar more likely that the disparate baseline charac-
eristics occurred because of chance. Moreover,and electrocardiographic evidence Am Heart J 2008;1low Grade in the entire study population between
he pexelizumab and placebo groups.
Although pexelizumab likely had little effect on
ither infarct size or clinical outcomes among pa-
ients with STEMI—only anterior infarct location
nd initial TIMI flow grade were significantly
ssociated with infarct size in a multivariate analy-
is—the results presented in this analysis further
mphasize the importance of early epicardial pa-
ency in the management of STEMI.
Numerous studies have shown a significant asso-
iation between initial TIMI flow grade at the time
f primary PCI and both infarct size and clinical
utcomes (11). Efforts to increase early patency,
ost specifically those aimed at improving door-to-
eperfusion time, have been associated with im-
roved clinical outcomes (12). Further pharmaco-
ogic strategies to improve early epicardial patency,
amely in the form of fibrinolytic therapy prior to
CI, have, however, been met with disappointing
esults to date (13).
Likewise, APEX-AMI failed to demonstrate any
angible benefit of complement inhibition in the
anagement of STEMI. Although this CMR sub-
tudy suggests that perhaps pexelizumab leads to a
ignificant reduction in infarct size, this may reflect,
t least in part, an imbalance in baseline character-
stics between the small patient populations. What
his substudy does support, however, is the contin-
ed pursuit of early epicardial patency as a means to
educe morbidity and mortality in STEMI.
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